title: Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer.
abstract: Five hundred and eighty-one patients with stage II-IV breast cancer were treated at Duke University Medical Center with high-dose chemotherapy, followed by hematopoietic support. All patients received a conditioning regimen of cyclophosphamide, cisplatin and carmustine. Of these patients, 15 (2.6%) developed symptoms similar to the hemolytic-uremic syndrome with evidence of thrombotic microangiopathy (TMA). The time of onset ranged from 75 days to 281 days post-transplant, with a median of 143 days. Hemolytic anemia and thrombocytopenia, without alternative cause, were required for diagnosis. All patients were treated with steroid therapy. In addition, 12 patients were treated primarily with plasmapheresis, and received a median of 46 treatments. Additional therapy included staphylococcal protein A column apheresis (eight patients), vincristine (three patients) and danazol (one patient). The mortality rate was 11 of 15 patients (73%). These patients had a median survival of 41 days from diagnosis of TMA (range 2-76 days). The four survivors are alive at 76, 186, 1837 and 2387 days from diagnosis of TMA. Three of these patients received twice daily plasmapheresis and protein A column apheresis therapy. One patient recovered without specific therapy. TMA is an infrequent complication of high-dose chemotherapy, but is associated with a high mortality. It frequently follows significant pulmonary drug toxicity. Survival may be improved with early diagnosis and aggressive plasmapheresis therapy.
authors.affiliation: Duke Bone Marrow Transplant Program, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Fisher
authors.forename: G B
authors.initials: GB
authors.lastname: Sherrill
authors.forename: A
authors.initials: A
authors.lastname: Hussein
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: J J
authors.initials: JJ
authors.lastname: Vredenburgh
authors.forename: M
authors.initials: M
authors.lastname: Elkordy
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.forename: W
authors.initials: W
authors.lastname: Petros
authors.forename: W P
authors.initials: WP
authors.lastname: Peters
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000401:mortality; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003613:Danazol / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced; D010956:Plasmapheresis; D010976:Platelet Count; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014182:Transplantation, Autologous; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D003613:Danazol